Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release

Author(s):  Bogner Robin H, Szwejkowski Jessica, Houston Alana

Issue:  Sep/Oct 2001 - Bioidentical Hormone Replacement Therapy
View All Articles in Issue

Page(s):  401-405

Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release Page 1
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release Page 2
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release Page 3
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release Page 4
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release Page 5

Download in electronic PDF format for $75

Abstract:  Morphine sulfate is often used to treat severe pain. Pharmacists have been requested to compound morphine sulfate sustained- release capsules in dosages that are not available commercially. However, there has been considerable controversy about the advisability of that practice. This study determined the release of six formulations of 300 mg morphine sulfate sustained- release capsules by means of a United States Pharmacopeia (USP) type III dissolution apparatus. The formulation suggested by a reputable compounding consulting company released almost half the morphine in the first hour of a timerelease test and did not adequately sustain the release of the remainder. With increases in the level of hydroxypropyl methylcellulose (Methocel), the release was prolonged and the amount of drug released during the first hour was reduced. One formulation of encapsulated compressed pellets showed that the release could be sustained significantly beyond that of the original formulation. In addition, the increased agitation that occurs in the gastrointestinal tract when the medication is taken after a meal reduced the period of sustained release and slightly increased the amount of morphine released during the first hour after administration. In conclusion, the original formula of morphine sulfate sustained-release capsules (Formula A) is probably not adequate for most applications. The formulations with a greater percentage of Methocel are preferred. In addition, the pelleted formulation was superior; however, it may not be feasible to use this labor-intensive approach to compound capsules.

Related Keywords: Morphine sulfate, slow-release capsules, effect of formulation on

Related Categories: PAIN MANAGEMENT, PEER-REVIEWED

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release
Bogner Robin H
, Szwejkowski Jessica, Houston Alana
Sep/Oct 2001
Pg. 401-405

In Vitro Studies on the Release of Morphine Sulfate from Compounded Slow-Release Morphine-Sulfate Capsules
Webster Kathy D
, Al-Achi Antoine, Greenwood Robert
Sep/Oct 1999
Pg. 409-411

In Vitro Evaluation of Extemporaneously Compounded Slow-Release Capsules Containing Morphine Sulfate or Oxycodone Hydrochloride
Glowiak Dana L
, Green Julie L, Bowman Bill J
Mar/Apr 2005
Pg. 157-164

Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Bakhteyar Hamid
, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
Sep/Oct 2017
Pg. 418-425

Custom-Compounded Micronized Hormones in a Slow-Release Capsule Matrix
Timmons Evelyn D
, Timmons Steven P
Sep/Oct 2002
Pg. 379

Compounding Slow-release Capsules: A Comprehensive Review and an Excel Spreadsheet for Faster Calculation of Excipients
Zur Eyal
Jan/Feb 2013
Pg. 10-22

Compounding of Slow-release Niacinamide Capsules: Feasibility and Characterization
Radojkovic Branko
, Milic Jela, Calija Bojan
Sep/Oct 2012
Pg. 434-437

Morphine Sulfate Slow-Release Suppositories
Allen Loyd V Jr
Jan/Feb 1997
Pg. 32-33

PreScription: Take Care with Terminology for Altered- and Slow-release Formulations
Allen Loyd V Jr
Nov/Dec 2003
Pg. 418

Liothyronine Sodium (T3) 5-mcg/Hydrocortisone 5-mg Slow-Release Capsules
Allen Loyd V Jr
Nov/Dec 2008
Pg. 545

Liothyronine Sodium (T3) 5-mcg/Selenium 100-mcg Slow-Release Capsules
Allen Loyd V Jr
Nov/Dec 2008
Pg. 547

Liothyronine Sodium (T3) 5-mcg Slow-Release Capsules
Allen Loyd V Jr
Nov/Dec 2008
Pg. 548

Progesterone 100-mg, Melatonin 1-mg, and L-Theanine 200-mg Slow-Release Capsules
Allen Loyd V Jr
Jan/Feb 2020
Pg. 62

Triple Estrogen 2.5-mg Slow-Release Capsules
Allen Loyd V Jr
Sep/Oct 1999
Pg. 401

Oxycodone 25-mg Slow-Release Capsules
Allen Loyd V Jr
Jan/Feb 2002
Pg. 49

Pharmaceutical Development of Enteric-Release Hard Gelatin Capsules in the Compounding Setting
de Oliveira Ferreira Anderson
, Holandino Carla
Mar/Apr 2008
Pg. 163-169

Basics of Compounding: Special Capsules
Allen Loyd V Jr
May/Jun 2016
Pg. 209-214

The Influence of Polymers, Surfactants, and Other Excipients on Naproxen Sodium Release from Matrices Prepared and the Effect of These Additives on the Swelling Rate of the Tablet
Alhmoud Hassan
, Akkam Yazan, Omari Derar, Alghananim Alaa, Melhem Mohammad Bani
Sep/Oct 2023
Pg. 431-439

Basics of Compounding: 3D Printing--Pharmacy Applications: Geometric Shape Effects on 3D Printing
Allen Loyd V Jr
Sep/Oct 2017
Pg. 388-392

Quality-Control Analytical Methods: Compounding Slow-Release Pharmaceuticals
Vu Nicole
, Kupiec Thomas C, Raj Vishnu
Mar/Apr 2009
Pg. 144-145

Return to Top